(June 15 18:30) Forbes.com
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has seen a solid 26% rise over the last twenty-one trading sessions, and we believe that the stock may continue to rally upward in the near term...
You can find the original article
here